Olink offers an unmatched high-multiplex technique to identify actionable biomarkers, with a strong focus on the human plasma proteome. Using minimal sample volume we provide quantifiable results with high-throughput, exceptional sensitivity, and specificity, with coverage across a broad dynamic range. Our mission is to accelerate proteomics together with the scientific community across multiple disease areas to enable new discoveries and better understand complex real-time human biology. We are committed to develop our offering and are continuously expanding our protein coverage for a growing number of biological processes and pathways.
Olink is well-established in Europe (HQ Uppsala, Sweden) and the USA (HQ Boston, MA), with a rapidly developing presence across Asia. We also work with a growing number of core labs around the world offering analysis and support to an expanding global customer base.
There are countless diseases that are in desperate need of new, more effective therapeutics to address unmet needs or to improve current standards of care. Addressing these needs is no easy task considering the long ... Continued
Why have we not been able to fully employ precision medicine? Many believe that this is due in large part to the inability to harness proteomics as the missing piece of the precision medicine puzzle....Continued
Olink provides a high throughput, cost-effective proteomics platform for screening ~1500 protein biomarkers using a minimal volume of sample. Since the beginning of the COVID-19 pandemic, researchers from around the world have been working tirelessly ... Continued